The development of galactosylated-chitosan-triptolide-nanoparticles (GC-TP-NPs) for liver cancer enhanced antitumor efficacy by inducing apoptosis through the TNF/NF-κB/Bcl-2 pathway, while minimizing systemic side effects [1029]. This evidence concerns the gene NFKB1 and liver cancer.